• Prophylaxis in kidney transplant rejection:
    • PO/IV 1g BD infused over ≥2 hours
      • Used concomitantly with cyclosporine and corticosteroids
  • Prophylaxis in heart transplant rejection:
    • PO/IV 1.5g BD infused over ≥2 hours
      • Used concomitantly with cyclosporine and corticosteroids
  • Prophylaxis in liver transplant rejection:
    • PO 1.5g BD infused over ≥2 hours
    • IV 1g BD infused over ≥2 hours
    • Used concomitantly with cyclosporine and corticosteroids
  • Lupus nephritis (Off-label):
    • PO 1g BD
    • Use with prednisolone
    • Consider decreasing dose 50% after 6 months of treatment
  • Tablet/capsule:
    • 180mg
    • 250mg
    • 360mg
    • 500mg
  • Take on empty stomach 1 hour before or 2 hours after meals
  • Once dosage is stabilized, can be taken with food after kidney transplant

Immunosuppressant

It inhibits T- and B-cell proliferation, as well as antibody production. It acts as a noncompetitive, selective and reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH)

  • Hypertension
  • Peripheral edema
  • Nausea
  • Vomiting
  • Diarrhea
  • Myelosuppression
  • Constipation
  • Infection
  • Hyperglycemia
  • Electrolyte abnormalities
  • Dyspnea
  • Leukocytosis
  • Edema
  • Tachycardia
  • Hypercholesterolemia
  • Insomnia
  • Increased BUN/Cr
  • UTI
  • Pleural effusion
  • Hypotension
  • Cough
  • Dizziness
  • Anxiety
  • Sepsis
  • Anorexia
  • Abnormal LFTs
  • Ascites
  • Tremor
  • Increased LDH
  • Dyspepsia
  • Rash
  • Paresthesia
  • Ecchymosis
  • Depression
  • Asthenia
  • Fever
  • Headache
  • Pain
  • Hypersensitivity
  • IV formulation in patients allergic to polysorbate 80
  • Pregnancy
  • Lesch-Nyhan syndrome
  • Kelly-Seegmiller syndrome
  • Blood donation during treatment and for at least 6 weeks after discontinuation
  • Semen donation during treatment and for at least 90 days after discontinuation

WARNING

  • Risk of first-trimester miscarriage and congenital malformations
  • Increased risk of lymphoma and other malignancies, particularly of skin
  • Increased risk of bacterial, viral, fungal and protozoal infections, including opportunistic infections and hepatitis B and C viral reactivation
  • Live vaccine
  • Cholestyramine
  • Colestipol

                          Drug Status

Availability Prescription only
Pregnancy Category D
Breastfeeding Weigh risk vs benefit
Schedule Not controlled
BRAND NAME STRENGTH FORMULATION PACK SIZE MANUFACTURER DISTRIBUTOR
Cellcept 500mg Tablet 50’s, 150’s F. Hoffman-La Roche Roche Kenya
Mofecon 500mg Tablet 60’s Prisma Pharma Wessex Pharma
Mofecon-S 360mg Tablet 60’s Prisma Pharma Wessex Pharma
Mofetyl 250mg Tablet 30’s RPG Life Sciences Pharma Specialities
Mofetyl 500mg Tablet 30’s RPG Life Sciences Pharma Specialities
Mofilet 500mg Tablet 60’s Emcure Pharma Lazor Pharma
Mphetas 500mg Tablet 10’s Intas Pharma Accord Healthcare
Mycept 250mg Capsule 30’s Panacea Biotec Europa Healthcare
Mycept 500mg Capsule 30’s Panacea Biotec Europa Healthcare
Myfortic 180mg Tablet 120’s Novartis Pharma Novartis Kenya
Myfortic 360mg Tablet 120’s Novartis Pharma Novartis Kenya
Mofilet S 500mg Tablet 60’s Emcure Pharma Lazor Pharma